Date: 2012-05-15
Type of information:
phase: 3
Announcement: recruitment of the first patient
Company: AB Science (France)
Product: masitinib
Action mechanism: Masitinib is a tyrosine kinase inhibitor that targets mast cells, important cells for immunity, as well as a limited number of kinases that play key roles in various cancers.
Disease: gastrointestinal stromal tumor (GIST)
Therapeutic area: Cancer - Oncology
Country:
Trial details: This phase III, multicenter, randomized, open-label, controlled, two-parallel group study is evaluating the efficacy and safety of masitinib as compared with sunitinib (Sutent®) in GIST patients after progression under imatinib (Gleevec®). This study will recruit around 200 patients from 50 sites around the world, randomized with a 1:1 ratio between masitinib and sunitinib. The primary end-point is overall survival.
Latest news:
